Valneva SE (FRA:AYJ)

Germany flag Germany · Delayed Price · Currency is EUR
2.784
+0.028 (1.02%)
Last updated: Jun 6, 2025
-27.39%
Market Cap 461.89M
Revenue (ttm) 186.06M
Net Income (ttm) -80.39M
Shares Out n/a
EPS (ttm) -0.54
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume n/a
Average Volume 7,417
Open 2.790
Previous Close 2.756
Day's Range 2.784 - 2.790
52-Week Range 1.739 - 4.224
Beta n/a
RSI 38.06
Earnings Date Aug 12, 2025

About Valneva SE

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease ca... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1998
Employees 713
Stock Exchange Frankfurt Stock Exchange
Ticker Symbol AYJ
Full Company Profile

Financial Performance

In 2024, Valneva SE's revenue was 169.58 million, an increase of 10.32% compared to the previous year's 153.71 million. Losses were -12.25 million, -87.93% less than in 2023.

Financial Statements

News

Valneva's Chikungunya Vaccine Advances With Pediatric Trial, Phase 3 In 2026

Valneva SE (NASDAQ: VALN) on Thursday announced six-month antibody persistence and safety data for its Phase 2 trial evaluating the safety and immunogenicity of two different dose levels of its singl...

1 day ago - Benzinga

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ

IXCHIQ was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after six months in both dose groups, alth...

1 day ago - Wallstreet:Online

Valneva Reports Positive Six-Month Antibody Persistence and Safety Phase 2 Results in Children for its Single-Shot Chikungunya Vaccine IXCHIQ®

Saint-Herblain (France), June 5, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced positive six-month antibody persistence and safety data for its Pha...

1 day ago - GlobeNewsWire

Valneva Announces Availability of Documentation for its Combined Shareholder Meeting and Provides Corporate Update

Saint-Herblain (France), June 4, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company (“the Company”), today announced the availability of documentation for its Combined ...

3 days ago - GlobeNewsWire

Valneva to Participate at U.S. and European Investor Conferences in June

Saint-Herblain (France), May 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and hold investor meetings ...

11 days ago - GlobeNewsWire

Valneva Provides Update on Recommended Use of IXCHIQ by Elderly Individuals in the United States

Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers ...

26 days ago - Wallstreet:Online

Valneva Provides Update on Recommended Use of IXCHIQ® by Elderly Individuals in the United States

Saint Herblain (France), May, 12 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Association (FDA) and the U.S. Centers ...

26 days ago - GlobeNewsWire

Valneva reports Q1 results

4 weeks ago - Seeking Alpha

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ in Elderly

Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Va...

4 weeks ago - Wallstreet:Online

Valneva Provides Update Following European Medicines Agency Announcement on Use of IXCHIQ® in Elderly

Saint Herblain (France), May, 07 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Medicines Agency (EMA) has started a review of Va...

4 weeks ago - GlobeNewsWire

Europe reviews Valneva's chikungunya vaccine after reports of serious side-effects in older people

The European Union's health regulator said on Wednesday it has begun a review of Valneva's chikungunya vaccine after reports of serious adverse events in older adults, including two deaths globally.

4 weeks ago - Reuters

Earnings Scheduled For May 7, 2025

Companies Reporting Before The Bell • Wallbox (NYSE: WBX) is estimated to report earnings for its first quarter. • Liberty Broadband (NASDAQ: LBRDK) is likely to report quarterly earnings at $0.00 p...

4 weeks ago - Benzinga

Valneva Reports First Quarter 2025 Financial Results and Provides Corporate Updates

Saint-Herblain (France), May 7, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported its financial results for the first quarter ending March 31, 2025, pr...

4 weeks ago - GlobeNewsWire

Insights Ahead: Valneva's Quarterly Earnings

Valneva (NASDAQ: VALN) will release its quarterly earnings report on Wednesday, 2025-05-07. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Valneva to report an e...

4 weeks ago - Benzinga

Valneva Provides Update on Recommendation for Use of Its Chikungunya Vaccine by French Authorities

Saint Herblain (France), April 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that France's national public health agency, the Haute Autorité d...

5 weeks ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Valneva SE (“Valneva” or the “Company”) (NASDAQ: VALN). Such investors are advised to cont...

6 weeks ago - GlobeNewsWire

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Valneva SE - VALN

NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Valneva SE ("Valneva" or the "Company") (NASDAQ:VALN). Such investors are advised...

6 weeks ago - Accesswire

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ Among U.S. Travelers

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for...

7 weeks ago - Wallstreet:Online

Valneva Provides Update on ACIP Recommendation for its Chikungunya Vaccine IXCHIQ® Among U.S. Travelers

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S. Centers for...

7 weeks ago - GlobeNewsWire

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ

Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, whic...

7 weeks ago - Wallstreet:Online

Valneva to Participate in Multiple Events at the 25th World Vaccine Congress, including a Presentation on its Chikungunya Vaccine IXCHIQ®

Saint-Herblain (France), April 16, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced its presence at the forthcoming 25th World Vaccine Congress, whic...

7 weeks ago - GlobeNewsWire